We are a leading developer and manufacturer of generic APIs in high-growth therapeutic areas of ARV, Oncology and Hepatitis Ci. We are amongst the top suppliers of APIs in the ARV therapeutic area to formulation companies catering to the fast-growing “donor-funded access-to-medicines” markets in Sub-Saharan Africa, South-East Asia and Latin America.

We believe our “research-first” approach has been critical to our success and it remains a clear differentiator. We are focused on undertaking dedicated R&D for our existing products and in areas with significant growth potential. We employ 750+ scientists at our R&D centres, which constitutes a quarter of our total employee strength.

We have three state-of-the-art manufacturing facilities in Visakhapatnam and a kilo lab facility in Hyderabad, which have received approvals from WHO, USFDA, PMDA, NIP, KFDA and BfArM. We adopt uniform manufacturing standards across all our facilities to achieve standardized product quality for all our markets.

We enjoy long-standing relationships with multinational pharmaceutical companies. Our top five customers have been with us for at least five years and these customers, in aggregate, contributed to approximately 67.8% of our total revenue. Our cumulative revenue from such customers has grown year over year for the last three financial years.

We are led by qualified and experienced promoters and key managerial personnel, who bring extensive expertise and understanding of the global generic pharmaceutical business. They also have a clear vision and leadership skills to organically scale up our business.

From our incorporation in 2005, we have delivered consistent growth both in terms of financial and operational metrics. Our total revenues have grown at a CAGR of 41.1% from FY 2012 to FY 2016 and our restated profit has grown at a CAGR of 57.5% between FY 2012 and FY 2016.

We are focused on growing our presence in key therapeutic areas, comprising of ARV, Hepatitis C and Oncology. We believe there are significant growth opportunities in the ARV therapeutic area because of the increasing HIV patient pool and WHO guidelines recommending early treatment for infected patients, regardless of age and viral load.

We intend to leverage our process chemistry skills to expand our API portfolio. We have developed several products in the anti-diabetic, cardiovascular and gastroenterology therapeutic areas. We are currently in the process of setting up dedicated facilities to manufacture these products.

We want to become a leading FDF player in the global generic pharmaceutical market. We believe that our presence in API production improves our ability to maintain quality and mitigates the demand-supply fluctuations that affect generics markets. It provides for consistency and reliability of supply in an increasingly regulated global environment.

We have a clear plan to work with global pharmaceutical companies to provide analytical and research services, clinical research supplies and commercial-scale contract manufacturing services. We also intend to provide services that help our partners improve process efficiency during the clinical phase of development.

We currently develop and manufacture specialty ingredients for use in nutraceutical, dietary supplements and cosmeceutical products. We are working on strengthening our presence in the manufacture of nature-identical substances. Our current portfolio of products are used as antioxidants, skin brighteners and UV protection agents.